In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TaconicArtemis GmbH

Division of Taconic Biosciences Inc.
www.artemispharma.de

Latest From TaconicArtemis GmbH

ITI Life Sciences: Scotland Minds the Funding Gap

Scotlands ITI Life Sciences aims to create a unique model for plugging the widening funding gap between publicly funded research and venture-funded commercialization of technology. The firm's first four programs reflect the various ways it aims to drum up life sciences business in Scotland.
Europe Business Strategies

Recent Dealmaking (3/2004)

Summarizing the month in European dealmaking.

Recent Dealmaking (01/2004)

Summarizing the month in European dealmaking.

Exelixis: Bartering for Growth

This genomics-based company has used business development as a strategic tool, swapping for key capacities that have helped it quickly leap forward. As the company demonstrated the merits of its model-organism platform, it began asking partners not for the most money they would give--but for assets that would help it forward integrate. One deal that started small expanded into a life-changing technology swap: from BMS, Exelixis got combinatorial chemistry capacity that it can now use to make compounds against its own targets. It also got a Phase II drug candidate for cancer, and rights to half of the molecules it makes for BMS, and Exelixis has used its new chemistry capacity to sign other barter-driven deals. Rapid evolution has risks: unless Exelixis accesses other fairly mature drug candidates, there will be a gap between launch of its first product and other compounds that haven't been tried yet in humans.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Artemis Biotech
  • Artemis Pharmaceuticals GMBH
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Taconic Biosciences Inc.
  • Senior Management
  • Peter Stadler, PhD, CEO
    Paul Rounding, Head, Bus. Dev.
  • Contact Info
  • TaconicArtemis GmbH
    Phone: (49) 221 964 53 10
    Neurather Ring 1
    Cologne, 51063
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register